Drug Profile
Rifalazil
Alternative Names: ABI 1648; KRM 1648; PA 1648Latest Information Update: 01 Feb 2018
Price :
$50
*
At a glance
- Originator Kaneka
- Developer ActivBiotics
- Class Antituberculars; Rifamycins
- Mechanism of Action DNA-directed RNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atherosclerosis; Chlamydial infections; Clostridium difficile infections; Helicobacter infections; Intermittent claudication; Leprosy; Mycobacterium avium complex infections; Tuberculosis
Most Recent Events
- 29 Jan 2018 Discontinued - Preclinical for Clostridium difficile infections in USA (PO) (ActivBiotics website, January 2018)
- 25 Apr 2013 ActivBiotics completes a phase IIb trial in Chlamydial infections in USA (NCT01631201)
- 01 Jul 2012 ActivBiotics initiates enrolment in a phase I trial for Chlamydial infections in USA (NCT01631201)